Pneumocon 13 Special Precautions

Do not vaccinate via intravenous route or by gluteal intramuscular injection, and ensure the syringe needle is not puncturing blood vessels during injection.
Check if the package, container, label, appearance and expiration date of the vaccine are in compliance with corresponding requirements before administration. Do not use the vaccine in case that any crack is observed in the container, loosened stopper, detached label, foreign particle(s) or discoloring inside the container, etc. Do not use the vaccine after the expiration date.
During storage, a white deposit and clear supernatant can be observed. This does not constitute a sign of deterioration. The vaccine should be shaken well to obtain a homogeneous white suspension prior to expelling air from the syringe, and should be inspected visually for any particulate matter and/or variation of physical aspect prior to administration. Do not use if the content appears otherwise.
Use immediately after unsealing. A single human dose shall be used up each time according to prescribing information.
The vaccination should be postponed in case of fever, acute diseases, and acute attack of chronic diseases.
Appropriate monitoring and medical care and rescue measures should be readily available in case of occurrence of rare hypersensitivity reactions during vaccination. If allergic reactions occur after vaccination, please go to the vaccination site or hospital in time.
Cautions should be taken for vaccination in recipients with thrombocytopenia, any coagulopathy or those who are receiving anticoagulant treatment.
Preterm infants should be monitored for the potential risk of apnea during primary series. For preterm infants under hospitalization (gestational age ≤30 weeks at birth) vaccinated with PCV13-TT according to the recommended immunization schedule, at least 48 hours of monitoring should be considered. Given the benefit of vaccination in preterm infants, discontinued or deferred vaccination of the product is not recommended.
Given that no safety and immunogenicity data are available for PCV13-TT in immuno-compromised individuals (e.g., malignancy or nephrotic syndrome), vaccination in this special group should be considered on an individual basis.
The use of PCV13-TT does not replace the use of 23-valent Pneumococcal Polysaccharide Vaccine in children ≥24 months of age with conditions such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immuno-compromised.
Under no circumstances shall the tetanus toxoid contained in the vaccine replace the routine immunization of tetanus vaccine or tetanus-containing vaccine.
This product cannot guarantee all recipients can be protected from any diseases caused by Streptococcus pneumoniae.